Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dalia Al-Mudallal

Gastroenterology Laguna Hills, CA Medical Doctor

NPI 1356502116 CMS profile 1283306

24411 Health Center Dr Ste 430, Laguna Hills, CA 92653

Open in the dashboard

General payments

$3,649

127 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dalia Al-Mudallal of Laguna Hills, CA is reported in the CMS Open Payments database as having received $3,649 across 127 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,814 16
2024 General $348 14
2023 General $366 19
2022 General $197 10
2021 General $357 21
2020 General $223 18
2019 General $346 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dalia Al-Mudallal
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Dalia Al-Mudallal were reported at $1,814. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Dalia Al-Mudallal Gastroenterology median Middle half National median
2019 $346 $417 $126–$1,100 $163
2020 $223 $224 $74–$624 $114
2021 $357 $352 $106–$1,054 $132
2022 $197 $448 $129–$1,270 $149
2023 $366 $533 $150–$1,390 $160
2024 $348 $605 $160–$1,606 $164
2025 $1,814 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Madrigal Pharmaceuticals $1,622 7 payments
  2. AbbVie, Inc. $634 30 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $595 40 payments
  4. Genzyme Corporation $179 8 payments
  5. Allergan Inc. $144 14 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $138 11 payments
  7. Regeneron Healthcare Solutions, Inc. $71 3 payments
  8. Intercept Pharmaceuticals, Inc. $70 4 payments
  9. Janssen Biotech, Inc. $64 3 payments
  10. Endogastric Solutions, Inc $26 1 payment
  11. Other $106 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,402 125 payments
  2. Travel and Lodging $1,247 2 payments
Products named General payments · program years 2019–2025
  1. XIFAXAN $572 38 payments
  2. RINVOQ $316 15 payments
  3. SKYRIZI $266 14 payments
  4. HUMIRA $253 13 payments
  5. DUPIXENT Immunology $179 8 payments
  6. LINZESS $174 15 payments
  7. TRULANCE Gastroenterology $143 9 payments
  8. TRULANCE Gastroenterology $130 10 payments
  9. ENTYVIO $78 5 payments
  10. DUPIXENT Inflammation And Immunology $71 3 payments
  11. Other $529 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

270

Median for Gastroenterology: 569

Drug cost

$24,266

Median for Gastroenterology: $104,976

Branded share of claims

14.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 12 $20,081
Pantoprazole Sodium Generic 91 $1,380
Famotidine Generic 113 $1,338
Cholestyramine Cholestyramine (With Sugar) Brand 15 $1,030
Omeprazole Generic 28 $258
Ondansetron Odt Ondansetron Brand 11 $179

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$61,944

Medicare's payments for the services billed

Medicare patients

281

Average age 73

Services billed

553

247 women, 34 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 41%
Osteoporosis 22%
Diabetes 20%
Depression 15%
Cancer 13%
Ischemic heart disease 11%
Chronic kidney disease 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
$112 — —
SKYRIZI
$77 — —
DUPIXENT
$51 — —
Quzyttir
$19 — —
XIFAXAN
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record